{
  "topic": "Mechanism of Action of Leflunomide",
  "questions": [
    {
      "question": "What is the primary mechanism of action of leflunomide?",
      "options": [
        "Inhibition of dihydroorotate dehydrogenase (DHODH)",
        "Inhibition of inosine monophosphate dehydrogenase (IMPDH)",
        "Blockade of interleukin-2 (IL-2) receptors",
        "Inhibition of calcineurin"
      ],
      "answer": "Inhibition of dihydroorotate dehydrogenase (DHODH)"
    },
    {
      "question": "Which enzyme does leflunomideâ€™s active metabolite (teriflunomide) specifically inhibit?",
      "options": [
        "Dihydroorotate dehydrogenase (DHODH)",
        "Xanthine oxidase",
        "Calcineurin",
        "Thymidylate synthase"
      ],
      "answer": "Dihydroorotate dehydrogenase (DHODH)"
    },
    {
      "question": "What is the primary effect of leflunomide on lymphocytes?",
      "options": [
        "Promotes lymphocyte proliferation",
        "Inhibits pyrimidine synthesis, reducing lymphocyte proliferation",
        "Enhances antigen presentation by dendritic cells",
        "Increases cytotoxic T-cell activity"
      ],
      "answer": "Inhibits pyrimidine synthesis, reducing lymphocyte proliferation"
    },
    {
      "question": "Which nucleotide synthesis pathway is primarily affected by leflunomide?",
      "options": [
        "De novo pyrimidine synthesis",
        "De novo purine synthesis",
        "Salvage pathway for pyrimidines",
        "Thymidine synthesis"
      ],
      "answer": "De novo pyrimidine synthesis"
    },
    {
      "question": "What is the active metabolite of leflunomide responsible for its immunosuppressive effects?",
      "options": [
        "Teriflunomide",
        "Leflunomide glucuronide",
        "Leflunomide phosphate",
        "A77 1726"
      ],
      "answer": "Teriflunomide"
    },
    {
      "question": "Which of the following cells is most affected by leflunomide due to their reliance on de novo pyrimidine synthesis?",
      "options": [
        "Erythrocytes",
        "Neutrophils",
        "Lymphocytes",
        "Platelets"
      ],
      "answer": "Lymphocytes"
    },
    {
      "question": "What is the primary clinical use of leflunomide in veterinary medicine?",
      "options": [
        "Treatment of bacterial infections",
        "Management of immune-mediated diseases (e.g., immune-mediated hemolytic anemia)",
        "Prevention of viral replication",
        "Treatment of fungal infections"
      ],
      "answer": "Management of immune-mediated diseases (e.g., immune-mediated hemolytic anemia)"
    },
    {
      "question": "Which of the following is a potential side effect of leflunomide therapy?",
      "options": [
        "Hyperglycemia",
        "Hepatotoxicity",
        "Nephrotoxicity",
        "Hypokalemia"
      ],
      "answer": "Hepatotoxicity"
    },
    {
      "question": "How does leflunomide affect the production of uridine monophosphate (UMP)?",
      "options": [
        "It promotes the conversion of dihydroorotate to orotate",
        "It inhibits the conversion of dihydroorotate to orotate",
        "It enhances the salvage pathway for pyrimidines",
        "It increases the production of thymidylate synthase"
      ],
      "answer": "It inhibits the conversion of dihydroorotate to orotate"
    },
    {
      "question": "Which of the following drugs has a similar mechanism of action to leflunomide but targets a different enzyme in the nucleotide synthesis pathway?",
      "options": [
        "Mycophenolate",
        "Azathioprine",
        "Cyclosporine",
        "Tacrolimus"
      ],
      "answer": "Mycophenolate"
    }
  ]
}